Registration Options

Activity Dates: 12/19/2019 - 12/19/2022

This course is closed. Please look for other available products in AAPP Education+Resources.

Target Audience

This activity is designed to meet the educational needs of pharmacists and other health care professionals who are interested in or managing the medication of patients with OUD.

Session Summary

During this session, participants will understand the development of the opioid epidemic, societal costs of OUD and injection drug use, the neurobiology of OUD and criteria to assess for OUD. Participants will also learn the regulatory requirements for medication management, the process for obtaining a DATA waiver and discuss methods to address and reduce stigma.


Course Requirements

You will proceed through the following steps to satisfactorily complete this course:

  • Sign in (or create a FREE account).
  • Register for this course.
  • Complete the pre-test before starting the activity.
  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date.
  • Complete the evaluation at the end of the activity.
  • If necessary, complete the post-test retest no later than the closing activity date.
  • Receive a passing grade (70%).
  • Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.

Participants in this course must complete an examination and achieve a score of 70% or greater. Up to two exam attempts are provided to each participant. Successful completion of the course also requires the completion of a course evaluation. Upon successful completion, ACPE credit is reported immediately to CPE Monitor although transcripts can be retrieved by participants online at

Faculty Information and Disclosures

Learning Objectives

  1. Describe the development of the opioid epidemic and the epidemiology of OUD in the United States.
  2. Explain the morbidity, mortality, and associated societal costs of OUD and injection drug use.
  3. Discuss the proposed neurobiology of OUD, including the roles of memory, genetics, and environmental factors.
  4. Apply the DSM-5 diagnostic criteria to assess for OUD.
  5. List methods to help address and reduce stigma associated with OUD.
  6. Describe regulatory and confidentiality requirements for medication management within a licensed opioid treatment program (OTP).
  7. Explain the regulatory requirements for obtaining a DATA waiver to prescribe buprenorphine/naloxone.

Continuing Education Credit and Disclosures

Activity Dates: 12/19/2019 - 12/19/2022
ACPE Contact Hours: 1.5
ACPE Number: 0284-0000-19-070-H08-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.

Grant Support

This activity is supported by an educational grant from Alkermes, Inc.